ATXA secures €2.5m in funding to research new cardiovascular drugs

The company is one of just three Irish companies to secure funding in this latest round

Professor Therese Kinsella of Ataxa Pharmaceuticals

ATXA Therapeutics, a University College Dublin (UCD) life sciences spin-out, which is developing novel therapeutic drugs to treat pulmonary arterial hypertension (PAH), and other related cardiovascular conditions, has secured €2.5 million in funding under the European Union’s Horizon 2020 SME Instrument Programme Phase 2.

The company is one of just three Irish companies to secure funding in this latest round. Only 64 companies from across Europe, out of 1,280 applications, were successful in ...